
usd pm et
summari make market comprehens line product servic
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
prior concern expect ew
sale grow billion
follow growth
fuel present strong data
support transcathet aortic valv
replac tavr procedur given
anticip neg impact
elect procedur volum
consum financ estim
ew sale growth like
mid- high-singl digit
ew largest segment tavr busi
sale think
rel insul recess think
tavr procedur volum could see rapid
bounc back worst
although tavr competit heat
think rapidli expand market
benefici major competitor
acceler like
posit data present march
subsequ august fda
approv ew tavr product low-risk
growth acceler follow
growth preced
base dcf model believ
share ew trade fair valu
recent lift opinion share ew
buy sell think share
fallen attract level recess
think ew well posit
net cash posit defens natur
product patient like requir
heart valv surgeri regardless econom
condit ew leader grow tavr
space continu innov ew
commit invest like
enabl establish leadership nascent
market minimally-invas transcathet
tricuspid mitral valv therapi tmtt
estim market tmtt grow
compound-annual-growth-rate
least billion
risk recommend target
macroeconom recoveri
slowdown growth world-wide tavr
market competit
target price base
dcf model reflect multipl
ew five-year averag
ep estim
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp ew develop manufactur market product
technolog design treat advanc stage cardiovascular diseas ew categor
product technolog four main area transcathet aortic valv replac tavr formerli
transcathet heart valv therapi segment surgic structur heart formerli surgic heart valv
therapi critic transcathet mitral tricuspid therapi tmtt
ew leader transcathet heart valv replac technolog design nonsurg
replac heart valv edward sapien famili valv transcathet aortic heart valv
use treat patient heart valv diseas tradit open-heart surgeri
sub-optimal ew began offer transcathet heart valv patient commerci europ
unit state japan sale ew transcathet heart valv repres
net sale respect
surgic structur heart segment core product line carpentier-edward perimount
pericardi valv platform includ valv aortic mitral surgic valv replac ew
leader surgic structur heart therapi includ product annuloplasti ring
beating-heart mitral repair system ew acquir harpoon medic inc decemb sale
ew surgic tissu heart valv product repres net sale
respect
critic segment make hemodynam monitor system ew world leader
measur patient heart function fluid statu surgic intens care set hemodynam
monitor enabl clinician balanc suppli demand oxygen critic ill patient
play import role enhanc surgic recoveri enabl appropri tissu organ perfus
ultim enabl improv patient outcom surviv sale ew core
hemodynam product repres net sale
ew tmtt segment work develop commerci transcathet heart valv repair
replac technolog design treat mitral tricuspid valv diseas
technolog earli clinic phase ew cardioband system mitral tricuspid valv
reconstruct commerci avail europ expect therapeut area experi rapid
growth come year
competit landscap cardiovascular diseas number one caus death world
top diseas term health care spend nearli everi countri cardiovascular diseas progress
tend worsen time often affect structur individu heart result
compani aim treat cardiovascular diseas highli profit face sever competit
cardiovascular segment medic technolog industri dynam subject signific
chang due cost-of-car consider regulatori reform industri custom consolid well
evolv patient need
tavr segment ew primari competitor includ plc boston scientif corpor
sale tavr surg present data march favor tavr
competitor includ plc plc critic ew compet
primarili varieti compani specif product line includ inc pulsion medic
system se lidco group plc transcathet mitral tricuspid therapi ew primari
competitor although mani compani develop effort
key maintain grow market share medic devic industri upkeep product
research develop program ew invest substanti effort spend
million sale compar million sale million
favor view ew increas spend expect compani continu
invest heavili
financi trend revenu grew billion billion five-year
compound annual growth rate compound-annual-growth-rate revenu year end decemb adjust
ep vs reflect five-year compound-annual-growth-rate ew typic maintain
net cash posit gener posit free cash flow defin cash flow oper less
capit expenditur free cash flow million vs million compani
capit structur posit cash flow provid compani substanti flexibl
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew fairli valu
neutral sinc februari technic indic ew
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
multipl ep high-end ew
five-year rang encourag sustain
ew long-term growth time see less upsid potenti share
high investor expect ep vs surpass
estim rais ep estim underli
sale growth acceler preced quarter driven
growth transcathet aortic valv replac tavr sale believ
present low risk data march key driver tavr growth
anticip fda approv sapien sapien ultra low surgic risk
patient ew made strateg decis discontinu centera valv
opt instead focu effort sapien ultra also expect strong
growth acceler sale mitral repair devic /kevin huang cfa
et cfra reiter buy opinion share
corpor maintain target
above-p multipl ep estim
higher end ew five-year rang encourag
sustain ew long-term growth ep vs
estim lift ep estim
underli basi net sale rose driven growth global
transcathet aortic valv replac tavr busi expect
introduct ew sapien ultra ultra centera tavr
system europ insignific impact sale growth manag
note ultra system differ predecessor mean
benefici ew properli educ clinician use continu
expect outstand potenti ew new system especi
anticip long-term tavr tailwind studi result /kevin
analyst research note compani news
pm et cfra rais opinion share buy
hold rais opinion ew share buy
hold primarili valuat keep price target ep estim
mention previou note think ew net cash posit
heavi exposur heart-rel medic procedur limit compani
downsid risk case potenti recess /kevin huang cfa
et cfra lift opinion share hold
sell lower target price
base discount cash flow model also lower ep estim
reflect anticip neg impact earn due
concurr lift opinion share ew think
trade close fair valu opinion ew net cash
posit heavi exposur heart-rel medic procedur limit
compani downsid risk case potenti recess /kevin
et cfra keep sell opinion share
corpor lift target base
discount cash flow model reflect multipl
ep estim ew five-year averag
ep vs fell short estim despit sale
beat ew aggress invest expand global tavr
transcathet aortic valv replac market increas field resourc
sale expand organ yoy billion sale grew
organ due impress strength tavr sale tavr
procedur whole market increas approxim yoy rais
ep estim reflect continu tavr
momentum commenc ep near futur expect
litig relat ew pascal devic sever countri draw
attent expect hear decis germani case
et cfra reiter sell opinion share
corpor lift target base
discount cash flow model reflect multipl
ep estim ew five-year averag ep
vs significantli exceed consensu estim strong
sale rais ep estim ep
underli sale growth acceler
driven underli growth transcathet
aortic valv replac tavr sale believ trial
evid behind growth acceler analyst earn call
seem think manag tavr guidanc low double-digit
growth conserv especi given anticip nearli rate
expect ew continu invest heavili
revenu drive growth continu believ share reflect overli
et cfra lower opinion share sell
hold base discount cash flow model use
optimist project lower price target share ew
price target reflect multipl ep
estim compar ew five-year rang
favor view ew capit structur long-term
sustain demand ew product believ share
recent trade near intrins valu key risk thesi
possibl see sustain substanti acceler
growth world-wide transcathet aortic valv replac tavr market
et cfra cut opinion share corp
hold buy lift target base
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd fiscal year analyst estim
ew earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
